Thesian Bio
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
Corporate information
- Company entity
- Thesian Bio
- Headquarters / principal office
- No verified public location identified
- Founded
- 2024 ↗
- Ownership / capital status
- Not verifiedi-Lab grant; equity funding stage not verified ↗
- Official corporate reference
- https://www.thesianbio.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2026-10-05 · i-Lab grant · Undisclosed ↗
French i-Lab non-equity award; amount not disclosed.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Founding / incorporation disclosure — scope stated in field
- Corporate ownership / financing disclosure